Valeant Pharmaceuticals International Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (79)

Latest Posts

About This Stock More About This Stock
Deutsche Raises Valeant Price Target On Extended Xifaxan Exclusivity
Article By: The Fly
Monday, April 30, 2018 3:42 PM EDT
The stay in the Xifaxan litigation between Valeant Pharmaceuticals and Teva was recently extended to July 30, 2018, from April 30, 2018, and may be extended further, Deutsche Bank analyst Gregg Gilbert tells investors in an intraday research note.
In this article: VRX, TEVA
Read
Valeant Move Higher Amid Debt Offering, Insider Buying
Article By: The Fly
Wednesday, March 14, 2018 5:30 PM EDT
Shares of specialty pharmacy company Valeant are higher this afternoon amid a relatively weak market backdrop.
In this article: VRX
Read
Deutsche Bank Says Buy Valeant After 'Significant Change' Over Last Two Years
Article By: The Fly
Monday, March 5, 2018 12:41 PM EDT
Shares of Valeant Pharmaceuticals are on the rise after Deutsche Bank analyst Gregg Gilbert upgraded the stock to Buy.
In this article: VRX
Read
Piper Calls Valeant Management 'Overly Rosy,' Cuts Price Target To $10
Article By: The Fly
Thursday, March 1, 2018 9:45 AM EDT
Management of Valeant Pharmaceuticals is taking an "overly rosy" long-term view of the business, Piper Jaffray analyst David Amsellem tells investors in a research note following the company's Q4 results.
In this article: VRX
Read
Can Valeant Bulls Stomach Double-Digit Revenue Declines?
Article By: Shock Exchange
Monday, February 26, 2018 7:17 AM EDT
Can VRX bulls stomach double-digit revenue declines? Asset sales have helped pare debt and reduce corporate overhead. Asset sales could be halted for the moment. If LOE exceeds revenue from new products then VRX's credit metrics could deteriorate.
In this article: VRX Also: PSHZF
Read

PARTNER HEADLINES

Latest Tweets for $VRX

No tweets yet!